Bayer focuses resources on growth and innovation
Planned net reduction of about 2,000 jobs worldwide by the end of 2012
To raise investment in further growth, annual cost savings of EUR 800 million are planned starting in 2013. About half of this amount is to be reinvested. By the end of 2012 the company is likely to take one-time charges in the region of EUR 1 billion, with part of this amount already being incurred in the fourth quarter of 2010.
In connection with this program, it is planned to reduce the global headcount of 108,700 by an aggregate of about 2,000 by 2012. Approximately 4,500 positions – including roughly 1,700 in Germany – are to be cut, while some 2,500 new jobs will be created over the same period, particularly in the emerging markets.
“Bayer has great business potential in all three subgroups. To better exploit this potential, we must continue to bundle existing resources and streamline our structures. That is the only way we can sustainably finance our investment in growth and innovation – for example in new pharmaceutical products, in our BioScience business and in the expansion of our capacities in Asia,” said Dekkers. “The cutbacks involved will not be easy, but they are necessary. I am convinced that with more innovation and less administration, Bayer can become a better and faster company.”
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.